glp-1 drugs cancer New study examines and breast risk GLP-1 weight-loss drugs might help

Moving beyond the function of the health behaviour: the effect of message frame on behavioural decision-making

Rather than a drug-specific anomaly, they noted that these trends point to a broader therapeutic role for incretin-based therapies in ocular health, with tirzepatide potentially amplifying this benefit

The results indicated that at 52 weeks, the weight reduction effects of mono-agonists, dual-agonists, and triple-agonists were 7.03 kg, 11.07 kg, and 24.15 kg, respectively

Sales of GLP-1 medications continue to rise, and Ozempic and Wegovy generate more than $25 billion in combined sales in 2024

You have several pathways to explore, each with different advantages

Patients with moderate kidney disease (eGFR 30-60) may use GLP-1 medications with careful monitoring, but severe kidney disease (eGFR below 30) makes compounded semaglutide inappropriate